EA200600101A1 - TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS - Google Patents

TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS

Info

Publication number
EA200600101A1
EA200600101A1 EA200600101A EA200600101A EA200600101A1 EA 200600101 A1 EA200600101 A1 EA 200600101A1 EA 200600101 A EA200600101 A EA 200600101A EA 200600101 A EA200600101 A EA 200600101A EA 200600101 A1 EA200600101 A1 EA 200600101A1
Authority
EA
Eurasian Patent Office
Prior art keywords
depression
treatment
affective disorders
gaboxadol
preparation
Prior art date
Application number
EA200600101A
Other languages
Russian (ru)
Inventor
Конни Санчес
Бьярке Эберт
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58707228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200600101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Priority claimed from PCT/DK2004/000459 external-priority patent/WO2004112786A2/en
Publication of EA200600101A1 publication Critical patent/EA200600101A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к применению габоксадола для приготовления фармацевтической композиции для лечения депрессии. Кроме того, оно относится к применению габоксадола для приготовления фармацевтической композиции, которая предназначена для использования в комбинации с ингибитором обратного захвата серотонина или любым другим соединением, которое вызывает повышение уровня внеклеточного серотонина.The present invention relates to the use of gaboxadol for the preparation of a pharmaceutical composition for the treatment of depression. In addition, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition that is intended for use in combination with a serotonin reuptake inhibitor or any other compound that causes an increase in extracellular serotonin.

EA200600101A 2003-06-25 2004-06-25 TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS EA200600101A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300956 2003-06-25
DKPA200400016 2004-01-07
PCT/DK2004/000459 WO2004112786A2 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Publications (1)

Publication Number Publication Date
EA200600101A1 true EA200600101A1 (en) 2006-06-30

Family

ID=58707228

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600101A EA200600101A1 (en) 2003-06-25 2004-06-25 TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS

Country Status (10)

Country Link
KR (1) KR20060025192A (en)
AR (1) AR047550A1 (en)
CA (2) CA2529805A1 (en)
CL (2) CL2004001607A1 (en)
EA (1) EA200600101A1 (en)
IS (1) IS8138A (en)
ME (2) MEP1908A (en)
NO (1) NO20060229L (en)
RS (1) RS20050911A (en)
TW (1) TW200509918A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120856A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics, Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2021236876A2 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
IS8138A (en) 2005-11-21
NO20060229L (en) 2006-01-16
CA2529805A1 (en) 2004-12-29
CL2010000166A1 (en) 2010-07-02
TW200509918A (en) 2005-03-16
AR047550A1 (en) 2006-01-25
CL2004001607A1 (en) 2005-05-27
RS20050911A (en) 2007-08-03
MEP1908A (en) 2010-02-10
CA2692334A1 (en) 2004-12-29
KR20060025192A (en) 2006-03-20
ME00030B (en) 2010-06-10

Similar Documents

Publication Publication Date Title
IL172631A0 (en) Gaboxadol for treating depression and other affective disorders
CY1117681T1 (en) 2,3-INDOLOAMINE DIAGNOSIS REGULATORS AND METHODS OF USING THESE
PA8596901A1 (en) P38 INHIBITORS AND METHODS OF USE OF THEM
EA200870019A1 (en) LACTAMIC CONNECTIONS AND METHODS OF THEIR APPLICATION
EA200970337A1 (en) SODIUM-GLUCOSE 2 COPHANTER OF INHIBITORS AND METHODS OF THEIR APPLICATION
EA201370208A1 (en) RIFAXIMINE FORMS AND THEIR APPLICATION
EA200700489A1 (en) NEW BENZO-CONDENSED HETEROARYL SULFAMIDE DERIVATIVES, USEFUL AS ANTI-CONVOLTIVE AGENT
EA200601746A1 (en) APPLICATION OF ROTIGOTINE FOR THE TREATMENT AND PREVENTION OF THE PARKINSONISM-PLUS SYNDROME
EA200901166A1 (en) CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS
NO20060242L (en) The combination of a serotonin reuptake inhibitor and agomelatine
DK1948606T3 (en) 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
EA200971141A1 (en) COMPOUNDS ACTIVATING TELOMERASE AND METHODS OF THEIR APPLICATION
EA200802072A1 (en) LIKOPIN FOR THE TREATMENT OF INFRINGEMENT OF SUBSTANCES
SE0401465D0 (en) New substituted piperdines as modulators of dopamine neurotransmission
AR047715A1 (en) ANALEPTIC AND ANTDEPRESSIVE COMBINATIONS
EA200501802A1 (en) COMBINATION OF ANALEPTIN MODAFINIL AND ANTIDEPRESSANT FOR THE TREATMENT OF DEPRESSION
EA200600101A1 (en) TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS
EA200600998A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A ZINC-HYALURONANE COMPLEX, INTENDED FOR THE TREATMENT OF SCATTERED SCLEROSIS
ATE536874T1 (en) TRIPLE MONOAMINE REUPPOST INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN
EA200600183A1 (en) COMBINATION OF SEROTONIN AND AGOMELATIN REVERSE CAPTURE INHIBITOR
EA200600534A1 (en) COMBINATION OF SEROTONIN AND SEAMOXIN RETURN CAPTURE INHIBITOR
NO20061427L (en) The combination of a serotonin reuptake inhibitor and amoxapine